

ACYCLOVIR OINT (CCHP2017)

Products Affected

Step 2:

- *acyclovir 5 % topical ointment*

Details

Criteria	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.
-----------------	---

ALPHAGAN (CCHP2017)

Products Affected

Step 2:

- ALPHAGAN P 0.1 % EYE DROPS
- COMBIGAN 0.2 %-0.5 % EYE DROPS
- SIMBRINZA 1 %-0.2 % EYE DROPS,SUSPENSION

Details

Criteria	Step Therapy requires trial of brimonidine 0.15% or brimonidine 0.2%.
-----------------	---

ANTIDEPRESSANT_NVT 2017

Products Affected

Step 2:

- DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR
- DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE
- *duloxetine 40 mg capsule, delayed release*
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule, extended release 24 hr*
- *fluvoxamine er 150 mg capsule, extended release 24 hr*
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.
-----------------	--

ARICEPT 23_NVT 2015

Products Affected

Step 2:

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

Details

Criteria	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.
-----------------	--

COPD

Products Affected

Step 2:

- INCRUSE ELLIPTA 62.5
MCG/ACTUATION POWDER FOR
INHALATION

Details

Criteria	Step Therapy requires a trial of Spiriva or Spiriva Respimat in previous 120 days.
-----------------	--

DEXILANT_2019

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	Step therapy requires trial of lansoprazole in the previous 120 days.
-----------------	---

DPP4

Products Affected

Step 2:

- JANUMET 50 MG-1,000 MG TABLET
- JANUMET 50 MG-500 MG TABLET
- JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE
- JANUVIA 100 MG TABLET
- JANUVIA 25 MG TABLET
- JANUVIA 50 MG TABLET

Step 3:

- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

Details

Criteria	Step Therapy requires trial of Metformin for Januvia, Janumet, or Janumet XR in the past 120 days. Trial of both Metformin AND Janumet, Janumet XR, OR Januvia required for Onglyza or Kombiglyze XR in the past 120 days.
-----------------	--

DRY EYE OTC (CCHP 2018)

Products Affected

Step 2:

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

Details

Criteria	
	Step Therapy requires trial of OTC artificial tears.

GLUCAGON

Products Affected

Step 2:

- BAQSIMI 3 MG/ACTUATION NASAL SPRAY
- GLUCAGEN HYPOKIT 1 MG INJECTION
- GLUCAGON EMERGENCY KIT (HUMAN-RECOMB) 1 MG SOLUTION FOR INJECTION

Details

Criteria	Step Therapy requires a trial of Gvoke in the previous 120 days.
-----------------	--

LAMA/LABA

Products Affected

Step 2:

- STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION

Details

Criteria	Step Therapy requires trial of ANORO.
-----------------	---------------------------------------

OPHTHALMIC ANTI-INFECTIVES_NVT 2015

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

Details

Criteria	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.
-----------------	--

PANCREATIC ENZYMES_NVT 2015

Products Affected

Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE

Details

Criteria
Step Therapy requires trial of CREON in previous 120 days.

POLYETHYLENE GLYCOL

Products Affected

Step 2:

- LINZESS 145 MCG CAPSULE
- LINZESS 290 MCG CAPSULE
- LINZESS 72 MCG CAPSULE
- MOVANTIK 12.5 MG TABLET
- MOVANTIK 25 MG TABLET
- RELISTOR 12 MG/0.6 ML
SUBCUTANEOUS SOLUTION
- RELISTOR 12 MG/0.6 ML
SUBCUTANEOUS SYRINGE
- RELISTOR 8 MG/0.4 ML
SUBCUTANEOUS SYRINGE

Details

Criteria	Step Therapy requires trial of OTC polyethylene glycol in the past 120 days.
-----------------	--

ST_RIVASTIGMINE_2019

Products Affected

Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*

Details

Criteria	Step Therapy requires trial of rivastigmine tablets in past 120 days.
----------	---

ST_SMOKINGCESS_2019

Products Affected

Step 2:

- *bupropion hcl 150 mg tablet, 12 hr sustained-release(smoking deterrent)*

Details

Criteria	
	Step therapy requires trial of nicotine patches in previous 120 days.

ULORIC_NVT 2015

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

Details

Criteria
Step Therapy requires trial of allopurinol in previous 120 days.

ZADITOR OTC (CCHP2017)

Products Affected

Step 2:

- *olopatadine 0.1 % eye drops*

Step 3:

- *olopatadine 0.2 % eye drops*
- PAZEO 0.7 % EYE DROPS

Details

Criteria	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml and PAZEO
-----------------	---

2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 12/2020

INDEX

A

acyclovir 5 % topical ointment.....1
ALPHAGAN P 0.1 % EYE DROPS2

B

BAQSIMI 3 MG/ACTUATION NASAL
SPRAY9
BESIVANCE 0.6 % EYE
DROPS,SUSPENSION11
bupropion hcl 150 mg tablet,12 hr sustained-
release(smoking deterrent)15

C

COMBIGAN 0.2 %-0.5 % EYE DROPS....2

D

DESVENLAFAXINE ER 100 MG
TABLET,EXTENDED RELEASE 24 HR
.....3
DESVENLAFAXINE ER 50 MG
TABLET,EXTENDED RELEASE 24 HR
.....3
DEXILANT 30 MG CAPSULE,
DELAYED RELEASE.....6
DEXILANT 60 MG CAPSULE,
DELAYED RELEASE.....6
donepezil 10 mg disintegrating tablet.....4
donepezil 5 mg disintegrating tablet.....4
DRIZALMA SPRINKLE 20 MG
CAPSULE,DELAYED RELEASE3
DRIZALMA SPRINKLE 30 MG
CAPSULE,DELAYED RELEASE3
DRIZALMA SPRINKLE 40 MG
CAPSULE,DELAYED RELEASE3
DRIZALMA SPRINKLE 60 MG
CAPSULE,DELAYED RELEASE3
duloxetine 40 mg capsule,delayed release...3

E

EMSAM 12 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3
EMSAM 6 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3
EMSAM 9 MG/24 HR TRANSDERMAL
24 HOUR PATCH.....3

F

febuxostat 40 mg tablet16
febuxostat 80 mg tablet16
FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE3
FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK3
FETZIMA 20 MG CAPSULE,EXTENDED
RELEASE.....3
FETZIMA 40 MG CAPSULE,EXTENDED
RELEASE.....3
FETZIMA 80 MG CAPSULE,EXTENDED
RELEASE.....3
fluvoxamine er 100 mg capsule,extended
release 24 hr.....3
fluvoxamine er 150 mg capsule,extended
release 24 hr.....3

G

gatifloxacin 0.5 % eye drops11
GLUCAGEN HYPOKIT 1 MG
INJECTION.....9
GLUCAGON EMERGENCY KIT
(HUMAN-RECOMB) 1 MG SOLUTION
FOR INJECTION.....9

I

INCRUSE ELLIPTA 62.5
MCG/ACTUATION POWDER FOR
INHALATION5

J

JANUMET 50 MG-1,000 MG TABLET7
JANUMET 50 MG-500 MG TABLET7
JANUMET XR 100 MG-1,000 MG
TABLET,EXTENDED RELEASE7
JANUMET XR 50 MG-1,000 MG
TABLET,EXTENDED RELEASE7
JANUMET XR 50 MG-500 MG
TABLET,EXTENDED RELEASE7
JANUVIA 100 MG TABLET7
JANUVIA 25 MG TABLET7
JANUVIA 50 MG TABLET7

2021 Chinese Community Health Plan Senior Select Program (HMO SNP)

Step Therapy Criteria
Updated 12/2020

K

KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE	7
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE	7
KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE	7

L

LINZESS 145 MCG CAPSULE	13
LINZESS 290 MCG CAPSULE	13
LINZESS 72 MCG CAPSULE	13

M

MARPLAN 10 MG TABLET	3
MOVANTIK 12.5 MG TABLET	13
MOVANTIK 25 MG TABLET	13

O

olopatadine 0.1 % eye drops	17
olopatadine 0.2 % eye drops	17
ONGLYZA 2.5 MG TABLET	7
ONGLYZA 5 MG TABLET	7

P

PANCREAZE 10,500 UNIT-35,500 UNIT- 61,500 UNIT CAPSULE,DELAYED RELEASE	12
PANCREAZE 16,800 UNIT-56,800 UNIT- 98,400 UNIT CAPSULE,DELAYED RELEASE	12
PANCREAZE 2,600 UNIT-6,200 UNIT- 10,850 UNIT CAPSULE,DELAYED RELEASE	12
PANCREAZE 21,000 UNIT-54,700 UNIT- 83,900 UNIT CAPSULE,DELAYED RELEASE	12

PANCREAZE 4,200 UNIT-14,200 UNIT- 24,600 UNIT CAPSULE,DELAYED RELEASE	12
PAZEO 0.7 % EYE DROPS	17

R

RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION	13
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE	13
RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE	13
RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE	8
rivastigmine 13.3 mg/24 hour transdermal patch	14
rivastigmine 4.6 mg/24 hour transdermal patch	14
rivastigmine 9.5 mg/24 hour transdermal patch	14

S

SIMBRINZA 1 %-0.2 % EYE DROPS,SUSPENSION	2
STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION	10

T

TRINTELLIX 10 MG TABLET	3
TRINTELLIX 20 MG TABLET	3
TRINTELLIX 5 MG TABLET	3

V

VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK	3
VIIBRYD 10 MG TABLET	3
VIIBRYD 20 MG TABLET	3
VIIBRYD 40 MG TABLET	3